Ultragenyx Pharmaceutical Inc.

RARE · Nasdaq · ·

Comparar

US$ 16,07-1,3%fechamento 13 de nov.

Números até 30 de setembro de 2026, do 10-Q arquivado em 4 de novembro de 2026

1W: +4,1%
1M: +5,9%

Just reported

Q3 2026 results

From Ultragenyx Pharmaceutical's results release of 3 de novembro de 2026; its quarterly report has since been filed.

Revenue
Actual
US$ 173M
+8,1% y/y
-19% q/q
Guided
—
No guide given
EPS, GAAP
Actual
-US$ 1,16
Guided
—
No guide given
Operating income, GAAP
Actual
-US$ 110M
Guided
—
No guide given

Company outlook

Full year 2026

RevenueUS$ 730M – US$ 760M+11% y/y Unchanged

Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.

Keep exploring

The themes Ultragenyx Pharmaceutical is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.

Highest-graded in Biotechnology

Graded A or B and worth $2B or more: A first, then the largest.

All 352 graded companies in its industry

Grade rose recently in Healthcare

Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.

All grade rises

Demonstrações financeiras completas →

Construído a partir dos próprios documentos de Ultragenyx Pharmaceutical Inc. entregues à Comissão de Valores Mobiliários dos EUA (SEC). Os números são os divulgados, com o histórico por ação recalculado para a base de ações de hoje. Isto descreve um negócio — não é recomendação de investimento nem sugestão de compra ou venda.

Ultragenyx Pharmaceutical Inc.

Ultragenyx Pharmaceutical Inc.

Q3 2026 results

Revenue

EPS, GAAP